Annals of Internal MedicineTirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes: A Randomized Clinical Trial

SURPASS-EARLY, a 794-patient open-label phase 4 RCT across 10 countries published in Annals of Internal Medicine, found tirzepatide superior to intensified conventional care (including GLP-1RAs) for HbA1c reduction (−1.99 vs. −1.32 percentage points), weight loss (ETD −8.0 kg), and waist circumference (ETD −6.2 cm) at 2 years in adults with early T2D on metformin.

Clinical Considerations

• 60.2% of tirzepatide patients achieved normoglycemia (HbA1c <5.7%) versus 24.0% on ICC — a clinically meaningful difference suggesting potential for disease remission framing in early-stage patients
• ICC arm permitted GLP-1RAs (excluding tirzepatide), making the comparator arm more rigorous than standard-of-care in many practice settings; tirzepatide’s superiority holds against an active, guideline-supported comparator
• Open-label design is a notable limitation — particularly for weight outcomes where behavioral effects can amplify measured differences
• Adverse event profiles were similar between arms, with GI events predominating in both; no new safety signals identified

Practice Applications

• Consider tirzepatide earlier in the T2D treatment sequence for patients with inadequate glycemic control on metformin, particularly those where weight reduction is also a clinical priority
• Recognize the normoglycemia rate as a potential conversation point with motivated early-stage patients — though remission durability beyond 2 years remains unstudied
• Interpret weight and waist circumference outcomes in the context of open-label design before weighting them equally with the HbA1c findings
• Monitor for forthcoming guidelines incorporating SURPASS-EARLY data into early T2D treatment algorithms